

Blocking human TSLP binding to HEK 293F/human TSLPR cells




Figure 1A

Blocking human TSLP binding to HEK293F/human TSLPR cells





Figure 1B

sample	KD(M)	kon(1/Ms)	kdis(1/s)
1-41	3.77E-09	1.84E+06	6.92E-03
1-51	2.66E-10	2.18E+06	5.80E-04
1-59	5.99E-11	2.64E+06	1.58E-04
3-18	4.85E-10	2.12E+06	1.03E-03
3-43	5.54E-11	2.44E+06	1.35E-04
5-31	1.15E-10	2.02E+06	2.31E-04
6-29	2.69E-10	1.43E+06	3.86E-04
7-54	2.26E-10	2.61E+06	5.88E-04
10-55	<1.0E-12	1.23E+06	<1.0E-07
10-63	9.45E-11	2.78E+06	2.63E-04
10-87	1.43E-10	1.82E+06	2.59E-04
11-6	<1.0E-12	1.41E+06	<1.0E-07
11-72	4.25E-10	1.53E+06	6.51E-04
11-75	1.30E-10	1.77E+06	2.30E-04

Figure 2

antibody	Bi-HuNb5-31	Bi-HuNb7-54	Bi-HuNb10-63
shake flask expression yield	475ug/mL	310ug/mL	510ug/mL

Figure 3



Sample	Bi-HuNb5-31	Bi-HuNb7-54	Bi-HuNb10-63	Tezepelumab
IC50(ug/ml)	0.0759	0.1410	0.0824	0.4920

Figure 4

Inhibiting Baf3/TSLPR/IL7R cells pSTAT5 induced by hTSLP




Figure 5